Studies of liver cancer radioimmunoimaging using anti-AFP monoclonal antibody

131I labeled anti-AFP monoclonal antibody IgG as radioimmunoimaging agent for tumor detection was studied in 32 patients with primary liver carcinoma. A positive rate of 90.6% was found in 29 cases, a false negative rate of 9.37% in three out of 32 patients. The positivity was related to tumor size rather than to the serum AFP level. Using double tracer-subtraction technique, the tumor foci became clearly visible and more easily identifiable in majority of the tumor imagings with gamma camera